drugset / Trial / NCT01158157
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
Phase 3
Completed
25 enrolled
Emergent BioSolutions
Centers for Disease Control and Prevention · collab
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to vaccinate plasma donors with ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
Timeline
- Start
- 2010-09-13
- Primary completion
- 2012-02-14
- Completion
- 2012-02-14
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACAM2000 | Vaccine | 2.5 ug | Other |